These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 1517380)

  • 21. Decreased concentration of 1,25-dihydroxyvitamin D3 receptors in peripheral mononuclear cells of patients with X-linked hypophosphatemic rickets: effect of phosphate supplementation.
    Nakajima S; Yamaoka K; Yamamoto T; Okada S; Tanaka H; Seino Y
    Bone Miner; 1990 Sep; 10(3):201-9. PubMed ID: 2171704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets.
    Baroncelli GI; Bertelloni S; Sodini F; Galli L; Vanacore T; Fiore L; Saggese G
    Pediatr Endocrinol Rev; 2004 Jun; 1(4):361-79. PubMed ID: 16437029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific internalization and action of 1,25-dihydroxyvitamin D3 in cultured dermal fibroblasts from patients with X-linked hypophosphatemia.
    Adams JS; Gacad MA; Singer FR
    J Clin Endocrinol Metab; 1984 Sep; 59(3):556-60. PubMed ID: 6547728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
    Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
    Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
    Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.
    Glorieux FH; Marie PJ; Pettifor JM; Delvin EE
    N Engl J Med; 1980 Oct; 303(18):1023-31. PubMed ID: 6252463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets.
    Alon U; Chan JC
    J Clin Endocrinol Metab; 1984 Apr; 58(4):671-5. PubMed ID: 6546575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets.
    Kruse K; Hinkel GK; Griefahn B
    Eur J Pediatr; 1998 Nov; 157(11):894-900. PubMed ID: 9835432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tertiary hyperparathyroidism during the treatment of familial hypophosphatemic rickets].
    Moreno Molina JA; López Siguero JP; Bueno Fernández A; Martínez-Aedo Ollero MJ; Martínez Valverde A
    An Esp Pediatr; 1996 Aug; 45(2):193-5. PubMed ID: 8967654
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.
    Gundberg CM; Cole DE; Lian JB; Reade TM; Gallop PM
    J Clin Endocrinol Metab; 1983 May; 56(5):1063-7. PubMed ID: 6601111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
    Raeder H; Shaw N; Netelenbos C; Bjerknes R
    Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypercalciuric hypophosphatemic rickets, mineral balance, bone histomorphometry, and therapeutic implications of hypercalciuria.
    Chen C; Carpenter T; Steg N; Baron R; Anast C
    Pediatrics; 1989 Aug; 84(2):276-80. PubMed ID: 2787497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets.
    Rivkees SA; el-Hajj-Fuleihan G; Brown EM; Crawford JD
    J Clin Endocrinol Metab; 1992 Dec; 75(6):1514-8. PubMed ID: 1464657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets.
    Econs MJ; Lobaugh B; Drezner MK
    J Clin Endocrinol Metab; 1992 Aug; 75(2):408-11. PubMed ID: 1639943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-linked hypophosphatemic rickets and the murine Hyp homologue.
    Hruska KA; Rifas L; Cheng SL; Gupta A; Halstead L; Avioli L
    Am J Physiol; 1995 Mar; 268(3 Pt 2):F357-62. PubMed ID: 7900834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia.
    Seikaly MG; Quigley R; Baum M
    Pediatr Nephrol; 2000 Nov; 15(1-2):57-9. PubMed ID: 11095012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical aspects of X-linked hypophosphatemic rickets.
    Chung WT; Niu DM; Lin CY
    Acta Paediatr Taiwan; 2002; 43(1):26-34. PubMed ID: 11890223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteomalacia in hereditary hypophosphatemic rickets with hypercalciuria: a correlative clinical-histomorphometric study.
    Gazit D; Tieder M; Liberman UA; Passi-Even L; Bab IA
    J Clin Endocrinol Metab; 1991 Jan; 72(1):229-35. PubMed ID: 1986023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical management and complications of X-linked hypophosphatemic vitamin D resistant rickets.
    Ono T; Seino Y
    Acta Paediatr Jpn; 1997 Aug; 39(4):503-7. PubMed ID: 9316301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density.
    Saggese G; Baroncelli GI; Bertelloni S; Perri G
    J Pediatr; 1995 Sep; 127(3):395-402. PubMed ID: 7658269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.